**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 5748**

**Columns: TOPIC HIGHLIGHT**

WJG 20th Anniversary Special Issues (9): Hepatitis B virus

**Outcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantation**

Congly SE *et al*. Viral hepatitis HIV co-infection liver transplantation

Stephen E Congly, Karen E Doucette, Carla S Coffin

**Stephen E Congly, Carla S Coffin**, Liver Unit, Division of Gastroenterology and Hepatology, University of Calgary, Calgary, AB T2N 4Z6, Canada

**Karen E Doucette**, Division of Infectious Diseases, University of Alberta, Edmonton, AB T6G 2R3, Canada

**Author contributions:** Congly SE, Doucette KE and Coffin CS solely contributed to this paper.

**Correspondence to: Carla S Coffin, MD, MSc, FRCPC**, Liver Unit, Division of Gastroenterology and Hepatology, University of Calgary, 6D21, Teaching, Research and Wellness Building 3280, Hospital Drive, Calgary, AB T2N 4Z6, Canada. cscoffin@ucalgary.ca

**Telephone:** +1-403-5925049 **Fax:** +1-403-5925090

**Received:** September 24, 2013  **Revised:** October 22, 2013

**Accepted:** November 3, 2013

**Published online:**

**Abstract**

Liver transplantation for human immunodeficiency virus (HIV) positive patients with viral hepatitis co-infection is increasingly offered in many North American and European liver transplant centers. Prior studies have demonstrated acceptable post-transplant outcomes and no increased risk of HIV complications in patients co-infected with hepatitis B virus (HBV). However, liver transplantation in HIV positive patients with hepatitis C virus (HCV) has poorer outcomes overall, requiring careful selection of candidates. This review aims to summarize the published literature on outcomes after transplant in HIV patients with HBV or HCV related end-stage liver disease and recommendations for management. In particular the pre-transplant factors impacting outcomes in HCV/HIV co-infected candidates and importance of multidisciplinary management will be discussed.

**Key words:** Hepatitis B virus; Human immunodeficiency virus co-infection; Hepatitis C virus; Co-infection; Liver transplantation

**Core tip:** Liver transplantation is not contraindicated in viral hepatitis patients co-infected with human immunodeficiency virus. Patients should meet standard listing criteria for liver transplantation. Management of these patients should be done through a multidisciplinary management approach including pharmacists and infectious diseases physicians.

Congly SE, Doucette KE, Coffin CS. Outcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantation. *World J Gastroenterol* 2013;

**Available from:** URL: http://www.wjgnet.com/esps/

**DOI:** http://dx.doi.org/10.3748/wjg.v19.i0.0000

**INTRODUCTION**

Liver transplantation offers the promise of improved quantity and quality of life for patients with end stage liver disease with 1-year survival approaching 90%[1]. Historically, HIV infection was considered to be a contraindication to transplantation[2] with early outcomes in the pre-highly active anti-retroviral (HAART) era being abysmal[3]. With the improvement of HAART, patients with HIV have comparable life expectancy to the general population[4,5]; similar to those with other chronic medical conditions, such as diabetes. As such, liver transplant is now considered a potential treatment option to the over 1.1 million infected with HIV in the United States[6] and 34 million worldwide[7].

Patients living with HIV have a significant burden of liver disease; one large series suggests that liver disease is related to over 14% of all cause mortality[8] with three-quarters of this being attributable to hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. The increased burden of co-infection with HBV or HCV in HIV patients relates to similar mechanisms of transmission of the viruses such as sexual or vertical transmission, blood transfusion or intravenous (*iv*) drug use. In areas of low HBV endemicity, such as North America and Western Europe, HIV and HBV co-infections occur primarily in immigrant populations and in adult populations due to shared sexual and percutaneous modes of transmission[9]. The prevalence of HBV co-infection in Western countries has been reported as between 6%-14%[10] with rates of co-infection in endemic areas such as Africa and southeast Asia nearing 30%[11]. For HCV, the rates of co-infection also reflect the shared risk factors for transmission with approximately 10% acquired through high risk sexual exposures and the vast majority via blood-borne contact[12]. The global burden of HIV co-infection is significant with approximately 7 million persons co-infected with HCV and 4 million with HBV worldwide[13,14].

**IMPACT OF VIRAL HEPATITIS/HIV CO-INFECTION**

Patients co-infected with either HBV or HCV have more aggressive liver disease than those with mono-infection. In a large epidemiological study of 23441 patients infected with HIV, HIV-HBV co-infected patients were reported to have a 3-fold higher risk of liver related mortality compared to HBV mono-infection[8]. Differences in survival were demonstrated in the early HAART era; a Taiwan study showed a 5-year survival of 75% in patients with HIV and chronic hepatitis B [positive serum hepatitis B surface antigen (HBsAg)] versus approximately 90% survival in HBsAg-negative, HIV infected patients[15]. A subsequent meta-analysis of the co-infected population was concordant with this finding, although HAART did reduce the risk of death from 1.6 (95%CI: 1.07-2.39) to 1.28 (95%CI: 1.07-2.39)[16]. Accordingly, HIV co-infected patients without HAART seem to have more aggressive HBV-related liver disease and progression to cirrhosis[17]. As well, HBV co-infection has also been demonstrated to adversely impact HIV patient outcomes either with or without HAART[18,19].

In HCV/HIV co-infection, the HCV disease course is negatively impacted with an increased HCV viral load as compared to HCV mono-infected patients[20] as well as accelerated fibrosis progression[21–24]. Insulin resistance in HCV mono-infected patients has been associated with increased fibrosis and impaired response to treatment[25,26] although in the co-infected population the impact of insulin resistance is less clear[27–30]. HCV co-infected patients have increased healthcare resource utilization[31] and increased mortality[32] versus those living with HCV alone. Treatment of HCV is often more complex, due to the interaction between HCV and HIV medications[33]. Further complicating matters is that co-infected patients have inferior responses to interferon and ribavirin based therapy; pooled analysis showed sustained virological response rates of 38% overall with genotypes 1 and 4 being 25% and genotype 2 and 3 being 60%[34] although the addition of protease inhibitors may lead to similar responses in genotype 1 infections[35]. The evidence that HIV disease activity is aggravated by HCV co-infection is controversial[36]. Nonetheless, achieving adequate control of the HIV with the use of HAART is important as it may reduce mortality as compared to no treatment[37] and reduce the rate of fibrosis to that of a HCV mono-infected patient[38] albeit may not completely achieve fibrosis regression[39].

**OUTCOMES AFTER LIVER TRANSPLANTATION IN HCV/HIV CO-INFECTION**

The published outcomes of HCV/HIV co-infected patients with regards to survival and HCV recurrence were analyzed in a recent meta-analysis[40]. This analysis compared HIV/HCV co-infected patients to those infected with HCV alone. There was no difference between groups with regards to the rate of acute cellular rejection (OR = 0.88; 95%CI: 0.44-1.76) or with regards to HCV recurrence rates (OR = 0.66; 95%CI: 0.27-1.59) although the evidence quality is described as being low. A significant reduction in survival was seen in co-infected patients compared to the HCV mono-infected population (HR = 2.81; 95%CI: 1.47-5.37) although this again was based on weaker evidence overall.More recently, there have been two large prospective multicenter cohort studies examining outcomes of HCV-HIV co-infection published. In Spain, a series of 86 consecutive HCV-HIV co-infected patients were compared to a matched series of 252 HCV mono-infected patients[41]. Patients with HIV were eligible if they met Spanish consensus guidelines[42] including CD4+ T cell counts > 100 cells/L (> 200 cells/L with history of opportunistic infection), suppressed HIV viral load and no AIDS defining events other than *Pneumocystis* pneumonia, esophageal candidiasis or tuberculosis.

In this cohort, 55% of the population had genotype 1 HCV infection and 15% were co-infected with HBV; the median model for end-stage liver disease (MELD) score at the time of transplant was 16 and the waitlist time was 4 mo. Notable differences between the HCV comparison group and the HCV/HIV co-infected group were lower rates of genotype 1 in the HCV mono-infected group, lower rates of acute rejection and lower rates of significant fibrosis (> Stage 2) with post-transplant recurrence of the HCV. Survival in the HCV/HIV co-infected group was similar in the first year (88% *vs* 90%) but diverged at 3 years (62% *vs* 76%) and 5 years post transplant (54% *vs* 71%). Similar rates and trends were seen for graft survival. Factors predicting poor survival on multivariate analysis included HCV genotype 1 and an increased donor risk index; having a low HCV RNA level had a significant protective effect. Low center experience was also independently associated with an increased risk of death.

The main North American experience published to date is based on data from the National Institutes of Health-sponsored Solid Organ Transplantation in HIV study. This multicenter United States trial compared a group of 86 HIV/HCV co-infected patients to HCV mono-infected patients and to all transplants in patients over the age of 65 years using the United Network for Organ Sharing (UNOS) database[2]. Eligible patients had similar entry criteria to the Spanish study including a CD4+ T cell count > 100 cells/L for 6 months and being on a stable HAART regimen for at least 3 months with undetectable viral loads; patients intolerant to HAART were allowed entry if they were predicted to have suppression of HIV post transplant based on past medication exposure and anti-HIV drug resistance testing. There was a more liberal policy regarding opportunistic infections in that after April 2002, patients with treated opportunistic infections (excluding lymphoma, visceral Kaposi’s sarcoma, chronic cryptosporidiosis and progressive multifocal leukoencephalopathy) were eligible for enrolment in the trial.

In this study, the HCV/HIV group was younger, had a lower body mass index (BMI), longer warm graft ischemic time and were more likely to have a deceased donor transplant than the HCV mono-infected group. More patients in the co-infected group received anti-HCV treatment. The co-infected group had significantly poorer survival compared to the HCV mono-infected population with 1-year survivals of 76% *vs* 92% and 3 year survivals of 60% *vs* 79%. The graft survival was also worse in HCV/HIV coinfected patients with 1-year graft survival rates of 72% *vs* 88% and 3 year graft survival of 53% *vs* 74%. The only factor identified as a risk factor for patient survival in this group was HIV infection. Risk factors for losing graft function included having a combined liver-kidney transplant (HR 3.8), BMI < 21 kg/m2 (HR 3.2), HCV+ donor (HR 2.5) and an older donor (HR 1.3/decade). Table 1 summarizes the data from the larger HCV trials published to date.

Based on the literature, several major risk factors for poor transplant survival in the HCV/HIV co-infected population have been reported. These include high MELD scores[43,44], HCV genotype 1[41], African descent[44], as well as viral load[41,44]. Few studies have looked at factors impacting graft survival; Terrault *et al*[2] identified that receiving either a HCV+ graft or an older organ, undergoing a simultaneous liver-kidney transplant or being underweight decreased graft survival. Fibrosing cholestatic hepatitis (FCH), an often fatal complication of hepatitis C post transplant is relatively uncommon in the mono-infected population with an incidence of about 5%-8%[41,45,46]. The incidence is increased in the co-infected population by two to three fold with the largest series suggesting a prevalence of 19%[41,44,47]. Commonly associated factors for FCH in the mono-infected population including acute rejection and older donor age[48] were not identified as predictors in the co-infected population[47].

**OUTCOMES AFTER LIVER TRANSPLANTATION IN HBV AND HIV CO-INFECTION**

In general, the results for HBV/HIV co-infected patients are very good and are similar to that of HBV mono-infected patients. One of the largest published series of HBV/HIV co-infected patients undergoing transplant consists of 22 patients predominantly from the Solid Organ Transplantation in HIV Multi-Site Study[49]. Patients were required to have either undetectable HIV viral loads or be predictably suppressible, CD4+ T cell count > 100 cells/L, absence of prior opportunistic infections and no history of visceral Kaposi’s sarcoma. Post transplantation, patients received a combination of hepatitis B immune globulin (HBIG) and antiviral therapy with indefinite use of HBIG targeting anti-HBs titers of > 100 IU/L; HBV antiviral treatment was based on their treatment prior to transplant. Co-infected patients were compared to patients with HBV undergoing transplantation at the University of California, San Francisco. Overall, the co-infected group was younger (median age 47 years *vs* 58 years), included more males (100% *vs* 65%) and fewer were transplanted for HCC as a primary indication (9% *vs* 25%). Both groups had similar donor characteristics other than the co-infected group receiving younger donors (39 years *vs* 51 years); immunosuppression regimens in the co-infected population were more likely to use cyclosporine and less likely to be receiving mycophenolate mofetil. The three-year survival of 85% was not significantly different to the HBV mono-infected population; there was no evidence of HBV disease activity in either group. Similar positive outcomes have been seen in other small trials (Table 2).

**ECONOMIC STUDIES OF CO-INFECTED LIVER TRANPLANTATION**

Liver transplant has significant cost to payers with estimated costs of transplant in the HCV mono-infected population of $169000 USD initially and subsequent annual costs of $38000[50]. Very limited study has been done on the economic impact of HIV on the cost of transplantation. One study estimated that the presence of HIV adds an additional cost of approximately $38000 to the cost of liver transplantation[40]. Further economic analyses to assess cost-effectiveness are needed.

**SELECTION OF HIV POSITIVE PATIENTS FOR LIVER TRANSPLANTATION**

Patients with HIV should meet the generally accepted indications for liver transplant as patients without HIV including advanced liver disease with a MELD of at least 15 or having an indication for an appealed MELD score (*i.e.*, MELD exception points) such as hepatocellular carcinoma, hepatopulmonary syndrome or portopulmonary syndrome[51]. They must be able to tolerate the surgery from a cardiovascular and respiratory standpoint and have a satisfactory psychosocial assessment. Patients with a history of substance abuse, including alcohol, must be abstinent and have completed a treatment program. Most programs, including ours, require a minimum of 6 mo of abstinence even though this interval is arbitrary[52].

Patients should be on a stable treatment regimen for their HIV with documented adherence and viral loads being undetectable for at least a 6-mo interval. Preferred antiretroviral agents as part of the HAART regimen include raltegravir, efavirenz, maraviroc and rilpivirine. Zidovudine and protease inhibitors are avoided when possible due to significant anemia and drug interactions respectively. Most nucleoside reverse transcriptase inhibitors can be used. Didanosine and stavudine are the only agents truly contraindicated given the risk of potentially fatal lactic acidosis. Antiretroviral therapy is now recommended in all HIV-infected patients, regardless of CD4 count, assuming they understand the risks and benefits of therapy and are committed to adherence[53]. In the context of potential transplantation and subsequent immunosuppression as well as the numerous options for therapy currently, we would recommend all patients be on HAART prior to transplant.

Current guidelines from the American Society of Transplantation (AST), based on the National Institute of Health studies, suggest that patients with no AIDS defining conditions should have a CD4+ T cell count > 100 cells/L and for patients with AIDS defining disease, a CD4+ T cell count >200 cells/L for at least 3 mo before transplant[54]. In practice, there may be significant variation between centers. In our center, we require a CD4 count ≥ 150 cells/L for at least 6 mo or, if the CD4 count is between 100-150, as is not uncommon in those with portal hypertension and hypersplenism, the CD4% should be ≥ 20% for at least 6 mo. Patients treated with interferon based anti-HCV treatment experience a drop in their absolute CD4 counts[55]. Therefore, to accurately reflect their immune status in the context of transplantation, they should have their CD4 count performed prior to beginning interferon treatment; a reasonable interval would be 4 to 6 mo. We consider a history of multi-drug resistant HIV a relative contraindication to transplantation given the potential challenges of controlling HIV post transplant; however as newer options for therapy continue to be developed, this needs to be reviewed on a case by case basis by the infectious diseases consultant to assess the likelihood of HIV viral breakthrough and the potential for future options.

In general, most opportunistic infections (OI) are not absolute contraindications to transplantation; absolute contraindications are listed in Table 3, which are congruent with the AST guidelines[54]. Patients should have been successfully treated for the OI with a reasonable interval of time elapsing following the completion of therapy to allow for immune reconstitution with HAART; we suggest at least 12 mo since the infection. Consultation with an infectious diseases specialist with regards to the risk of recurrence post transplant as well as the need for any additional prophylactic therapies post transplant is also recommended.

For the HIV/HCV co-infected patient, simultaneous liver-kidney transplantation is not recommended given poor outcomes[2] as compared to the mono-infected HCV patient[56]. Similarly, HCV positive grafts should be avoided in HIV co-infected patients given inferior survival[2]. Patients should ideally have a BMI > 21 kg/m2; in otherwise acceptable candidates with BMIs < 21 kg/m2, nutritional supplementation and reassessment once the BMI exceeds 21 is reasonable; this is in keeping with the 2013 AST guidelines[54]. We would suggest that patients with natural MELD scores > 25 be reviewed on a case by case given the worse outcomes seen in this population. Additionally, it is recognized that co-infected patients have more rapid deterioration of liver disease and a higher risk of death on the list than mono-infected patients[1,57], thus a detailed discussion of potential benefit of live donor liver transplantation should occur. At this time, we do not recommend re-transplantation of patients with HIV/HCV co-infection outside of study protocols given the poor 42% 3 year survival seen in a small series of 14 patients[58].

**SUMMARY OF RECOMMENDATIONS FOR THE PRE-TRANSPLANT MANAGEMENT OF THE PATIENT WITH HIV AND VIRAL HEPATITIS CO-INFECTION**

In co-infected HCV patients, successful treatment of HCV will likely offer significant improvement in transplant outcomes given the adverse effects of recurrent HCV in the co-infected[44] and mono-infected HCV populations[59] as well as increased mortality on the waitlist[60]. However, treatment can be challenging due to the interaction of novel directly acting anti-HCV agents (*i.e.*, viral protease and polymerase inhibitors) with HAART[33] especially in the context of advanced liver disease and risk of decompensation. If treatment is not feasible, complications of liver disease should be managed similar to the non-HIV infected population.

For patients with HIV-HBV co-infection, the ideal antiretroviral regimen should contain tenofovir, with appropriate dose adjustment for renal function. If tenofovir is poorly tolerated, entecavir is suggested in conjunction with a fully suppressive HIV treatment regimen. If patients have any history of lamivudine exposure, given high rates of lamivudine resistant HBV in the co-infected population, it is recommended that if entecavir is used, it be at a 1 mg dose daily.

Both HBV/HIV and HCV/HIV co-infected patients with HCC seem to have a higher risk of tumor progression outside of most transplant centers’ criteria including the current UNOS standard of the Milan criteria[61], and total tumor volume[62]. Given this, we would obtain imaging every 3 mo to monitor tumor development. As well, given that an AFP rise of > 15 μg/L per month is associated with a poor prognosis in this population[63], it is suggested that AFP be done monthly as a marker of tumor progression.

**SUMMARY OF RECOMMENDATIONS FOR THE POST TRANSPLANT MANAGEMENT OF THE HIV/VIRAL HEPATITIS CO-INFECTED PATIENT**

***Immunosuppression***

Overall, immunosuppression in the HIV co-infected population is similar in principle to that of the mono-infected patient. The use of an induction agent is controversial; however, given high rejection rates seen[2], we feel that the use of the interleukin 2 inhibitor basiliximab as a steroid sparing agent is reasonable. Thymoglobulin would not be recommended given the high rate of graft loss seen in the HIV renal transplant group due to increased HCV replication[64]. The maintenance immunosuppression regimen in HIV-positive recipients is not well defined, and even less is known in HCV/HIV in co-infected patients[54]. Most programs have used calcineurin inhibitors as the backbone of the maintenance protocol with cyclosporine potentially having some in vivo suppression of HIV[65] although cyclosporine may put patients at higher risk of rejection as compared to tacrolimus[64] and may lead to poorer outcomes in the HCV population[66]. Mycophenolate mofetil as an adjunct agent may have anti-HCV[67] and anti HIV effects[68,69]. Sirolimus may be considered as a calcineurin inhibitor-sparing agent in the context of renal insufficiency. As well, sirolimus may reduce HIV replication through blocking of the HIV entry receptor, CCR5[70], has antitumor properties in HCC[71] and demonstrated improved outcomes in a small series of HIV/HCV coinfected patients[72]. However, analysis of the Scientific Registry of Transplant Recipients database showed worse graft survival and overall HCV patient survival[73] as well as an increased risk of hepatic artery thrombosis[74]. Thus the risk-benefit ratio of sirolimus will need to be carefully considered.

Medication management in HIV positive transplant recipients is challenging due to bidirectional drug interactions between immunosuppressants and antiretrovirals which may lead to altered drug exposure, toxicity, rejection or poorly controlled HIV[75]. Close communication between pharmacists managing the HIV antivirals and immunosuppression will be critical. Therefore, both the HIV team and the transplant teams should be informed about any medication changes. Antiretroviral therapy should be given up to the time of transplant and then restarted as soon as possible post transplant once oral therapy is tolerated and ideally no longer than a week post operatively; generally in well suppressed patients before transplant, the HIV viral loads will not rebound within that time-frame. If there is poor oral absorption, HAART levels may be sub-therapeutic leading to increased risk of resistance and viral breakthrough. The key drug-drug interactions are summarized in Table 4.

***Prophylaxis***

In HBV patients post transplant, most patients initially receive HBIG as prophylaxis for recurrent infection[76]. The use of a potent HBV medication such as tenofovir or entecavir is also recommended. Likely, with suppression of HBV with a newer nucleos(t)ide analogue, HBIG may be able to be stopped in many patients[77–79] or may not even be required[80]. In the context of a HBV-HIV co-infected patient, until further data exists with regards to HBIG sparing therapy, we would use HBIG in combination with tenofovir or entecavir with consideration of indefinite HBIG use due to a high incidence of occult HBV post liver transplant as well as to account for possible anti-HBV drug interruptions.

Given the immunodeficiency from the HIV as well as the antirejection medication, infection prophylaxis is critical (Table 5). From an infection standpoint, perioperative prophylaxis to cover gastrointestinal pathogens, including *Enterococcus*, as well as *Candida* in those at high risk, in addition to cytomegalovirus prophylaxis with valganciclovir is identical to patients without HIV. All co-infected patients should remain on lifelong prophylaxis for *Pneumocystis jirovecii* pneumonia with one tablet of single strength trimethoprim/sulfamethoxazole daily. For those intolerant, alternatives include monthly inhaled pentamidine, oral dapsone or atovaquone.

***Summary of post transplant management issues in HIV/viral hepatitis co-infection***

**Rejection:** Patients with HIV are at increased risks of acute cellular rejection[2,41]; careful monitoring is required. Given the increased risk, protocol biopsies are recommended peritransplant at baseline, 6 mo, 12 mo and then annually subsequently. When rejection is clinically suspected, a biopsy should be obtained. The preferred method to treat rejection is to increase calcineurin inhibitor levels or sirolimus levels depending on the agent being used, as well as increasing mycophenolate mofetil levels. Use of anti-lymphocyte depleting agents, such as thymoglobulin, is to be avoided if possible due to prolonged immunosuppression of T cells with thymoglobulin[81]. High dose steroids in the context of HCV co-infection leads to more aggressive disease activity and rapid progression in fibrosis[82].

**Occult HBV:** In patients who have occult HBV (HBsAg negative, HB core antibody positive), we would suggest annual monitoring of HBsAg levels. Given most HAART regimens includes medication that has activity for HIV and HBV, such as tenofovir, emtricitabine or lamivudine, reactivation is low risk, especially with the use of tenofovir.

**Recurrent HCV:** Treatment of the hepatitis C should be offered post-transplantation when there is histologic evidence of recurrent disease. Earlier therapy in disease may be associated with improved outcomes in the mono-infected population[83] and thus consideration could be given to starting therapy in all HIV/HCV co-infected liver transplantation recipients once stable and on low dose maintenance immunosuppression. HIV/transplant pharmacists should be consulted with regards to drug selection given the complex three-way interactions between HCV protease inhibitors, antiretroviral agents and immunosuppressants.

Treatment of hepatitis C is critical with the presentation of fibrosing cholestatic hepatitis (FCH) given its marked effect on survival. Currently, the typical treatment is the use of pegylated interferon and ribavirin with a median survival of 22 mo; this is about 20% the survival of co-infected HCV-HIV patients without fibrosing cholestatic hepatitis[47]. Recently, there has been two reports of the use of a protease inhibitor (telaprevir and boceprevir[84]) including in a co-infected patient[85] with good effect, although careful monitoring of the calcineurin inhibitors is needed with both telaprevir and boceprevir[86]. One case report exists of the combination of sofosbuvir and daclatasvir being successfully used to treat FCH[87]; these drugs are not yet commercially available. Thus, consideration may be currently given to triple therapy for managing FCH given its abysmal prognosis with likely better-tolerated and more efficacious therapy to come.

**CONCLUSION**

# Significant advances have been made with regards to transplanting patients with HIV including those with viral hepatitis co-infection. Transplanted HBV co-infected patients obtain similar outcomes to the HBV mono-infected patient with outcomes less successful in the HCV co-infected population. Treatment of HCV offers the best chance of improved outcomes. Many new treatment strategies for HCV are in advanced stages of development including pan-genotypic interferon free regimens and it is likely these regimens will allow for easier treatment of HCV and improved survival post transplant.

# Currently, in the United States, organs cannot be knowingly transplanted from donors with HIV by federal law[88] with similar policies existing in Canada[89,90] Given the current armamentarium of antiretroviral medications and the ability to suppress HIV, there is potentially a pool of organs that could be used to benefit patients with HIV; one model suggests that over 500-600 patients with HIV could benefit from receiving organs from donors also infected with HIV[91]. A series of 14 patients with HIV receiving HIV positive kidneys has showed good 1 year outcomes suggesting that this may be a viable option[92]. Currently, legislation passed in the United States Senate looks to change federal policy; the HIV Organ Policy Equity Act would enable HIV positive organs to be used in HIV positive patients[93]. With this development, further research can then be conducted with regards to outcomes and determining the appropriate population these organs can be used in. In the future, further delineation of the optimal HCV/HIV co-infected candidate will be identified so as to bring outcomes closer to that of the HCV mono-infected patient.

**REFERENCES**

1 **Kim WR**, Stock PG, Smith JM, Heimbach JK, Skeans MA, Edwards EB, Harper AM, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2011 Annual Data Report: liver. *Am J Transplant* 2013; **13** Suppl 1: 73-102 [PMID: 23237697 DOI: 10.1111/ajt.12021]

2 **Terrault NA**, Roland ME, Schiano T, Dove L, Wong MT, Poordad F, Ragni MV, Barin B, Simon D, Olthoff KM, Johnson L, Stosor V, Jayaweera D, Fung J, Sherman KE, Subramanian A, Millis JM, Slakey D, Berg CL, Carlson L, Ferrell L, Stablein DM, Odim J, Fox L, Stock PG. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. *Liver Transpl* 2012; **18**: 716-726 [PMID: 22328294 DOI: 10.1002/lt.23411]

3 **Gordon FH**, Mistry PK, Sabin CA, Lee CA. Outcome of orthotopic liver transplantation in patients with haemophilia. *Gut* 1998; **42**: 744-749 [PMID: 9659174]

4 **Lohse N**, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sørensen HT, Vaeth M, Obel N. Survival of persons with and without HIV infection in Denmark, 1995-2005. *Ann Intern Med* 2007; **146**: 87-95 [PMID: 17227932]

5 **Nakagawa F**, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. *Curr Opin Infect Dis* 2013; **26**: 17-25 [PMID: 23221765 DOI: 10.1097/QCO.0b013e32835ba6b1]

6 **Centers for Disease Control and Prevention**. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 U.S. dependent areas—2010. HIV Surveillance Supplemental Report 2013; 18 (No. 2, part B) [Internet]. 2013. Available from: http: //www.cdc.gov/hiv/topics/ surveillance/resources/reports/#supplemental

7 **Joint United Nations Programme on HIV/AIDS, United Nations**. Global Report: UNAIDS Report on the Global AIDS epidemic: 2012 [Internet]. [Geneva]: UNAIDS; 2012 [cited 2013 Sep 3]. Available from: http: //www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120\_UNAIDS\_Global\_Report\_2012\_en.pdf

8 **Weber R**, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte Ad, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD. Liver-related deaths in persons infected with the human immunodeficiency virus: the D: A: D study. *Arch Intern Med* 2006; **166**: 1632-1641 [PMID: 16908797 DOI: 10.1001/archinte.166.15.1632]

9 **McGovern BH**. The epidemiology, natural history and prevention of hepatitis B: implications of HIV coinfection. *Antivir Ther* 2007; **12** Suppl 3: H3-13 [PMID: 18284178]

10 **Alter MJ**. Epidemiology of viral hepatitis and HIV co-infection. *J Hepatol* 2006; **44**: S6-S9 [PMID: 16352363 DOI: 10.1016/j.jhep.2005.11.004]

11 **Koziel MJ**, Peters MG. Viral hepatitis in HIV infection. *N Engl J Med* 2007; **356**: 1445-1454 [PMID: 17409326 DOI: 10.1056/NEJMra065142]

12 **Eisenbach C**, Merle U, Stremmel W, Encke J. Liver transplantation in HIV-positive patients. *Clin Transplant* 2009; **23** Suppl 21: 68-74 [PMID: 19930319 DOI: 10.1111/j.1399-0012.2009.01112.x]

13 **Soriano V**, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, Mauss S, Rockstroh J. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. *AIDS* 2008; **22**: 1399-1410 [PMID: 18614862 DOI: 10.1097/QAD.0b013e3282f8b46f]

14 **Soriano V**, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. *Antiviral Res* 2010; **85**: 303-315 [PMID: 19887087 DOI: 10.1016/j.antiviral.2009.10.021]

15 **Sheng WH**, Kao JH, Chen PJ, Huang LM, Chang SY, Sun HY, Hung CC, Chen MY, Chang SC. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy. *Clin Infect Dis* 2007; **45**: 1221-1229 [PMID: 17918088 DOI: 10.1086/522173]

16 **Nikolopoulos GK**, Paraskevis D, Hatzitheodorou E, Moschidis Z, Sypsa V, Zavitsanos X, Kalapothaki V, Hatzakis A. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. *Clin Infect Dis* 2009; **48**: 1763-1771 [PMID: 19435436 DOI: 10.1086/599110]

17 **Di Martino V**, Thevenot T, Colin JF, Boyer N, Martinot M, Degos F, Coulaud JP, Vilde JL, Vachon F, Degott C, Valla D, Marcellin P. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. *Gastroenterology* 2002; **123**: 1812-1822 [PMID: 12454838 DOI: 10.1053/gast.2002.37061]

18 **Chun HM**, Roediger MP, Hullsiek KH, Thio CL, Agan BK, Bradley WP, Peel SA, Jagodzinski LL, Weintrob AC, Ganesan A, Wortmann G, Crum-Cianflone NF, Maguire JD, Landrum ML. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. *J Infect Dis* 2012; **205**: 185-193 [PMID: 22147794 DOI: 10.1093/infdis/jir720]

19 **Tsai MS**, Chang SY, Lo YC, Yang CJ, Sun HY, Liu WC, Wu PY, Hung CC. Hepatitis B virus (HBV) coinfection accelerates immunologic progression in patients with primary HIV infection in an area of hyperendemicity for HBV infection. *J Infect Dis* 2013; **208**: 1184-1186 [PMID: 23840045 DOI: 10.1093/infdis/jit299]

20 **Neukam K**, García-Rey S, Cifuentes C, Macías J, Mira JA, Vázquez MJ, Parra-Sánchez M, Palomares JC, Merchante N, Di Lello FA, Pineda JA. HIV-coinfection leads to a modest increase in plasma HCV-RNA load in patients with chronic HCV infection. *Antiviral Res* 2012; **95**: 212-215 [PMID: 22750672 DOI: 10.1016/j.antiviral.2012.06.009]

21 **de Lédinghen V**, Barreiro P, Foucher J, Labarga P, Castéra L, Vispo ME, Bernard PH, Martin-Carbonero L, Neau D, García-Gascó P, Merrouche W, Soriano V. Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. *J Viral Hepat* 2008; **15**: 427-433 [PMID: 18221303 DOI: 10.1111/j.1365-2893.2007.00962.x]

22 **Soto B**, Sánchez-Quijano A, Rodrigo L, del Olmo JA, García-Bengoechea M, Hernández-Quero J, Rey C, Abad MA, Rodríguez M, Sales Gilabert M, González F, Mirón P, Caruz A, Relimpio F, Torronteras R, Leal M, Lissen E. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. *J Hepatol* 1997; **26**: 1-5 [PMID: 9147999]

23 **Mohsen AH**, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, Wiselka M, Norris S. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. *Gut* 2003; **52**: 1035-1040 [PMID: 12801963]

24 **Benhamou Y**, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. *Hepatology* 1999; **30**: 1054-1058 [PMID: 10498659 DOI: 10.1002/hep.510300409]

25 **Romero-Gómez M**. Insulin resistance and hepatitis C. *World J Gastroenterol* 2006; **12**: 7075-7080 [PMID: 17131467]

26 **Laurito MP**, Parise ER. Association between insulin resistance and sustained virologic response in hepatitis C treatment, genotypes 1 versus 2 and 3: systematic literature review and meta-analysis. *Braz J Infect Dis* 2013; **17**: 555-563 [PMID: 24055394 DOI: 10.1016/j.bjid.2013.02.009]

27 **Hull MW**, Rollet K, Moodie EE, Walmsley S, Cox J, Potter M, Cooper C, Pick N, Saeed S, Klein MB. Insulin resistance is associated with progression to hepatic fibrosis in a cohort of HIV/hepatitis C virus-coinfected patients. *AIDS* 2012; **26**: 1789-1794 [PMID: 22739388 DOI: 10.1097/QAD.0b013e32835612ce]

28 **Ryan P**, Resino S, Miralles P, Cosín J, López JC, Moreno S, Catalán P, Ramírez M, Gutiérrez I, Berenguer J. Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus. *J Acquir Immune Defic Syndr* 2010; **55**: 176-181 [PMID: 20577091 DOI: 10.1097/QAI.0b013e3181e5b1f0]

29 **Merchante N**, de los Santos-Gil I, Merino D, González-Serrano M, Mira JA, Sanz-Sanz J, Fernández-Fuertes E, Ruiz-Morales J, del Valle J, Macías J, Moro A, Pineda JA. Insulin resistance is not a relevant predictor of sustained virological response to pegylated interferon plus ribavirin in HIV/HCV co-infected patients. *J Hepatol* 2009; **50**: 684-692 [PMID: 19231001 DOI: 10.1016/j.jhep.2008.10.032]

30 **Merchante N**, Macías J, Ramayo E, Vergara S, García-García JA, Mira JA, Corzo JE, Gómez-Mateos JM, Lozano F, Pineda JA. Insulin resistance is not associated with liver fibrosis progression in HIV/hepatitis C virus-coinfected patients. *J Viral Hepat* 2006; **13**: 449-456 [PMID: 16792538 DOI: 10.1111/j.1365-2893.2005.00708.x]

31 **Linas BP**, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, Rong J, Sax PE, Walensky RP, Schouten J, Freedberg KA. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. *J Viral Hepat* 2011; **18**: 506-512 [PMID: 20546501 DOI: 10.1111/j.1365-2893.2010.01325.x]

32 **Ananthakrishnan AN**, McGinley EL, Fangman J, Saeian K. Hepatitis C/HIV co-infection is associated with higher mortality in hospitalized patients with hepatitis C or HIV. *J Viral Hepat* 2010; **17**: 720-729 [PMID: 20002558 DOI: 10.1111/j.1365-2893.2009.01232.x]

33 **Rodríguez-Torres M**. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient. *Curr Opin Infect Dis* 2013; **26**: 50-57 [PMID: 23242341 DOI: 10.1097/QCO.0b013e32835c2027]

34 **Davies A**, Singh KP, Shubber Z, Ducros P, Mills EJ, Cooke G, Ford N. Treatment outcomes of treatment-naïve Hepatitis C patients co-infected with HIV: a systematic review and meta-analysis of observational cohorts. *PLoS One* 2013; **8**: e55373 [PMID: 23393570 DOI: 10.1371/journal.pone.0055373]

35 **Martel-Laferrière V**, Brinkley S, Bichoupan K, Posner S, Stivala A, Perumalswami P, Schiano T, Sulkowski M, Dieterich D, Branch A. Virological response rates for telaprevir-based hepatitis C triple therapy in patients with and without HIV coinfection. *HIV Med* 2013; Epub ahead of print [PMID: 24025147 DOI: 10.1111/hiv.12086]

36 **Rockstroh JK**, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, Kirk O, Phillips A, Ledergerber B, Lundgren J. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. *J Infect Dis* 2005; **192**: 992-1002 [PMID: 16107951 DOI: 10.1086/432762]

37 **Qurishi N**, Kreuzberg C, Lüchters G, Effenberger W, Kupfer B, Sauerbruch T, Rockstroh JK, Spengler U. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. *Lancet* 2003; **362**: 1708-1713 [PMID: 14643119 DOI: 10.1016/S0140-6736(03)14844-1]

38 **Bräu N**, Salvatore M, Ríos-Bedoya CF, Fernández-Carbia A, Paronetto F, Rodríguez-Orengo JF, Rodríguez-Torres M. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. *J Hepatol* 2006; **44**: 47-55 [PMID: 16182404 DOI: 10.1016/j.jhep.2005.07.006]

39 **Thein HH**, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. *AIDS* 2008; **22**: 1979-1991 [PMID: 18784461 DOI: 10.1097/QAD.0b013e32830e6d51]

40 **Health Quality Ontario**. Kidney and liver organ transplantation in persons with human immunodeficiency virus: An Evidence-Based Analysis. *Ont Health Technol Assess Ser* 2010; **10**: 1-56 [PMID: 23074407]

41 **Miro JM**, Montejo M, Castells L, Rafecas A, Moreno S, Agüero F, Abradelo M, Miralles P, Torre-Cisneros J, Pedreira JD, Cordero E, de la Rosa G, Moyano B, Moreno A, Perez I, Rimola A. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. *Am J Transplant* 2012; **12**: 1866-1876 [PMID: 22471341 DOI: 10.1111/j.1600-6143.2012.04028.x]

42 **Miró JM**, Torre-Cisnero J, Moreno A, Tuset M, Quereda C, Laguno M, Vidal E, Rivero A, Gonzalez J, Lumbreras C, Iribarren JA, Fortún J, Rimola A, Rafecas A, Barril G, Crespo M, Colom J, Vilardell J, Salvador JA, Polo R, Garrido G, Chamorro L, Miranda B. [GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005)]. *Enferm Infecc Microbiol Clin* 2005; **23**: 353-362 [PMID: 15970168]

43 **Duclos-Vallée JC**, Féray C, Sebagh M, Teicher E, Roque-Afonso AM, Roche B, Azoulay D, Adam R, Bismuth H, Castaing D, Vittecoq D, Samuel D. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. *Hepatology* 2008; **47**: 407-417 [PMID: 18098295 DOI: 10.1002/hep.21990]

44 **de Vera ME**, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, Marcos A, Demetris A, Jain A, Fung JJ, Ragni MV. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. *Am J Transplant* 2006; **6**: 2983-2993 [PMID: 17062005 DOI: 10.1111/j.1600-6143.2006.01546.x]

45 **Satapathy SK**, Sclair S, Fiel MI, Del Rio Martin J, Schiano T. Clinical characterization of patients developing histologically-proven fibrosing cholestatic hepatitis C post-liver transplantation. *Hepatol Res* 2011; **41**: 328-339 [PMID: 21426450 DOI: 10.1111/j.1872-034X.2011.00781.x]

46 **Schluger LK**, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC, Fiel I, Zhang D, Gerber MA, Miller CM, Bodenheimer HC. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. *Hepatology* 1996; **23**: 971-976 [PMID: 8621177 DOI: 10.1002/hep.510230505]

47 **Antonini TM**, Sebagh M, Roque-Afonso AM, Teicher E, Roche B, Sobesky R, Coilly A, Vaghefi P, Adam R, Vittecoq D, Castaing D, Samuel D, Duclos-Vallée JC. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. *Am J Transplant* 2011; **11**: 1686-1695 [PMID: 21749638 DOI: 10.1111/j.1600-6143.2011.03608.x]

48 **Verna EC**, Abdelmessih R, Salomao MA, Lefkowitch J, Moreira RK, Brown RS. Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. *Liver Transpl* 2013; **19**: 78-88 [PMID: 23081888 DOI: 10.1002/lt.23559]

49 **Coffin CS**, Stock PG, Dove LM, Berg CL, Nissen NN, Curry MP, Ragni M, Regenstein FG, Sherman KE, Roland ME, Terrault NA. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. *Am J Transplant* 2010; **10**: 1268-1275 [PMID: 20346065 DOI: 10.1111/j.1600-6143.2010.03070.x]

50 **McAdam-Marx C**, McGarry LJ, Hane CA, Biskupiak J, Deniz B, Brixner DI. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. *J Manag Care Pharm* 2011; **17**: 531-546 [PMID: 21870894]

51 **O'Leary JG**, Lepe R, Davis GL. Indications for liver transplantation. *Gastroenterology* 2008; **134**: 1764-1776 [PMID: 18471553 DOI: 10.1053/j.gastro.2008.02.028]

52 **Rice JP**, Lucey MR. Should length of sobriety be a major determinant in liver transplant selection? *Curr Opin Organ Transplant* 2013; **18**: 259-264 [PMID: 23492643 DOI: 10.1097/MOT.0b013e32835fb94b]

53 **Panel on Antiretroviral Guidelines for Adults and Adolescents.** Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [Internet]. Department of Health and Human Services; Available from: http: //aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf

54 **Blumberg EA**, Rogers CC. Human immunodeficiency virus in solid organ transplantation. *Am J Transplant* 2013; **13** Suppl 4: 169-178 [PMID: 23465009 DOI: 10.1111/ajt.12109]

55 **HCV working group of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) in EuroCoord.** Effect of hepatitis C treatment on CD4+ T-cell counts and the risk of death in HIV-HCV-coinfected patients: the COHERE collaboration. *Antivir Ther* 2012; **17**: 1541-1550 [PMID: 22869294 DOI: 10.3851/IMP2263]

56 **del Pozo AC**, Martín JD, Rodriguez-Laiz G, Sturdevant M, Iyer K, Schwartz M, Schiano T, Lerner S, Ames S, Bromberg J, Thung S, de Boccardo G. Outcome of combined liver and kidney transplantation in hepatitis C: a single-center long-term follow-up experience. *Transplant Proc* 2009; **41**: 1713-1716 [PMID: 19545713 DOI: 10.1016/j.transproceed.2009.02.103]

57 **Murillas J**, Rimola A, Laguno M, de Lazzari E, Rascón J, Agüero F, Blanco JL, Moitinho E, Moreno A, Miró JM. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. *Liver Transpl* 2009; **15**: 1133-1141 [PMID: 19718643 DOI: 10.1002/lt.21735]

58 **Gastaca M**, Aguero F, Rimola A, Montejo M, Miralles P, Lozano R, Castells L, Abradelo M, Mata Mde L, San Juan Rodríguez F, Cordero E, Campo Sd, Manzardo C, de Urbina JO, Pérez I, Rosa Gde L, Miro JM. Liver retransplantation in HIV-infected patients: a prospective cohort study. *Am J Transplant* 2012; **12**: 2465-2476 [PMID: 22703615 DOI: 10.1111/j.1600-6143.2012.04142.x]

59 **Burton JR**, Everson GT. Management of the transplant recipient with chronic hepatitis C. *Clin Liver Dis* 2013; **17**: 73-91 [PMID: 23177284 DOI: 10.1016/j.cld.2012.09.013]

60 **Ragni MV**, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. *Liver Transpl* 2005; **11**: 1425-1430 [PMID: 16237709 DOI: 10.1002/lt.20534]

61 **Mazzaferro V**, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med* 1996; **334**: 693-699 [PMID: 8594428 DOI: 10.1056/NEJM199603143341104]

62 **Toso C**, Trotter J, Wei A, Bigam DL, Shah S, Lancaster J, Grant DR, Greig PD, Shapiro AM, Kneteman NM. Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. *Liver Transpl* 2008; **14**: 1107-1115 [PMID: 18668667 DOI: 10.1002/lt.21484]

63 **Vibert E**, Duclos-Vallée JC, Ghigna MR, Hoti E, Salloum C, Guettier C, Castaing D, Samuel D, Adam R. Liver transplantation for hepatocellular carcinoma: the impact of human immunodeficiency virus infection. *Hepatology* 2011; **53**: 475-482 [PMID: 21274869 DOI: 10.1002/hep.24062]

64 **Stock PG**, Barin B, Murphy B, Hanto D, Diego JM, Light J, Davis C, Blumberg E, Simon D, Subramanian A, Millis JM, Lyon GM, Brayman K, Slakey D, Shapiro R, Melancon J, Jacobson JM, Stosor V, Olson JL, Stablein DM, Roland ME. Outcomes of kidney transplantation in HIV-infected recipients. *N Engl J Med* 2010; **363**: 2004-2014 [PMID: 21083386 DOI: 10.1056/NEJMoa1001197]

65 **Sokolskaja E**, Olivari S, Zufferey M, Strambio-De-Castillia C, Pizzato M, Luban J. Cyclosporine blocks incorporation of HIV-1 envelope glycoprotein into virions. *J Virol* 2010; **84**: 4851-4855 [PMID: 20181694 DOI: 10.1128/JVI.01699-09]

66 **Irish WD**, Arcona S, Bowers D, Trotter JF. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. *Am J Transplant* 2011; **11**: 1676-1685 [PMID: 21564522 DOI: 10.1111/j.1600-6143.2011.03508.x]

67 **Henry SD**, Metselaar HJ, Lonsdale RC, Kok A, Haagmans BL, Tilanus HW, van der Laan LJ. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. *Gastroenterology* 2006; **131**: 1452-1462 [PMID: 17101321 DOI: 10.1053/j.gastro.2006.08.027]

68 **Hawley T**, Spear M, Guo J, Wu Y. Inhibition of HIV replication in vitro by clinical immunosuppressants and chemotherapeutic agents. *Cell Biosci* 2013; **3**: 22 [PMID: 23672887 DOI: 10.1186/2045-3701-3-22]

69 **Margolis DM**, Kewn S, Coull JJ, Ylisastigui L, Turner D, Wise H, Hossain MM, Lanier ER, Shaw LM, Back D. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. *J Acquir Immune Defic Syndr* 2002; **31**: 45-49 [PMID: 12352149]

70 **Heredia A**, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, Klingebiel E, Gallo RC, Redfield RR. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. *Proc Natl Acad Sci U S A* 2003; **100**: 10411-10416 [PMID: 12915736 DOI: 10.1073/pnas.1834278100]

71 **Menon KV**, Hakeem AR, Heaton ND. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. *Aliment Pharmacol Ther* 2013; **37**: 411-419 [PMID: 23278125 DOI: 10.1111/apt.12185]

72 **Di Benedetto F**, Di Sandro S, De Ruvo N, Montalti R, Ballarin R, Guerrini GP, Spaggiari M, Guaraldi G, Gerunda G. First report on a series of HIV patients undergoing rapamycin monotherapy after liver transplantation. *Transplantation* 2010; **89**: 733-738 [PMID: 20048692 DOI: 10.1097/TP.0b013e3181c7dcc0]

73 **Watt KD**, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database. *Liver Transpl* 2012; **18**: 1029-1036 [PMID: 22641474 DOI: 10.1002/lt.23479]

74 **Molinari M**, Berman K, Meeberg G, Shapiro JA, Bigam D, Trotter JF, Kneteman N. Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. *Transpl Int* 2010; **23**: 155-168 [PMID: 19765266 DOI: 10.1111/j.1432-2277.2009.00969.x]

75 **van Maarseveen EM**, Rogers CC, Trofe-Clark J, van Zuilen AD, Mudrikova T. Drug-drug interactions between antiretroviral and immunosuppressive agents in HIV-infected patients after solid organ transplantation: a review. *AIDS Patient Care STDS* 2012; **26**: 568-581 [PMID: 23025916 DOI: 10.1089/apc.2012.0169]

76 **Congly SE**, Burak KW, Coffin CS. Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation. *Expert Rev Clin Immunol* 2011; **7**: 429-436 [PMID: 21790285 DOI: 10.1586/eci.11.30]

77 **Wesdorp DJ**, Knoester M, Braat AE, Coenraad MJ, Vossen AC, Claas EC, van Hoek B. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. *J Clin Virol* 2013; **58**: 67-73 [PMID: 23880162 DOI: 10.1016/j.jcv.2013.06.035]

78 **Fung J**, Chan SC, Cheung C, Yuen MF, Chok KS, Sharr W, Chan AC, Cheung TT, Seto WK, Fan ST, Lai CL, Lo CM. Oral nucleoside/nucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B. *Am J Gastroenterol* 2013; **108**: 942-948 [PMID: 23629601 DOI: 10.1038/ajg.2013.111]

79 **Teperman LW**, Poordad F, Bzowej N, Martin P, Pungpapong S, Schiano T, Flaherty J, Dinh P, Rossi S, Subramanian GM, Spivey J. Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. *Liver Transpl* 2013; **19**: 594-601 [PMID: 23447407 DOI: 10.1002/lt.23628]

80 **Gane EJ**, Patterson S, Strasser SI, McCaughan GW, Angus PW. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. *Liver Transpl* 2013; **19**: 268-274 [PMID: 23447403 DOI: 10.1002/lt.23600]

81 **Carter JT**, Melcher ML, Carlson LL, Roland ME, Stock PG. Thymoglobulin-associated Cd4+ T-cell depletion and infection risk in HIV-infected renal transplant recipients. *Am J Transplant* 2006; **6**: 753-760 [PMID: 16539632 DOI: 10.1111/j.1600-6143.2006.01238.x]

82 **Ciesek S**, Wedemeyer H. Immunosuppression, liver injury and post-transplant HCV recurrence. *J Viral Hepat* 2012; **19**: 1-8 [PMID: 22187942 DOI: 10.1111/j.1365-2893.2011.01548.x]

83 **Roche B**, Samuel D. Hepatitis C virus treatment pre- and post-liver transplantation. *Liver Int* 2012; **32 Suppl 1**: 120-128 [PMID: 22212582 DOI: 10.1111/j.1478-3231.2011.02714.x]

84 **Al Nahdi N**, Ford JA, Greanya ED, Harrigan JA, Tse I, Steinbrecher UP, Erb SR, Yoshida EM. First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder. *Ann Hepatol* 2013; **12**: 156-160 [PMID: 23293209]

85 **Antonini TM**, Furlan V, Teicher E, Haim-Boukobza S, Sebagh M, Coilly A, Bonhomme-Faivre L, Peytavin G, Roque-Afonso AM, Vittecoq D, Samuel D, Taburet AM, Duclos-Vallée JC. Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft. *AIDS* 2013; **27**: 2655-2657 [PMID: 23939241 DOI: 10.1097/01.aids.0000432539.77711.f4]

86 **Kiser JJ**, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. *Hepatology* 2012; **55**: 1620-1628 [PMID: 22331658 DOI: 10.1002/hep.25653]

87 **Fontana RJ**, Hughes EA, Bifano M, Appelman H, Dimitrova D, Hindes R, Symonds WT. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. *Am J Transplant* 2013; **13**: 1601-1605 [PMID: 23593993 DOI: 10.1111/ajt.12209]

88 **OPTN.** OPTN Policy 2 Minimum Procurement Standards for an Organ Procurement Organization (OPO) [Internet]. Available from: http: //optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy\_2.pdf

89 **Health Canada.** Guidance Document for Cell, Tissue and Organ Establishments - Safety of Human Cells, Tissues and Organs for Transplantation [Internet]. Available from: http: //www.hc-sc.gc.ca/dhp-mps/brgtherap/reg-init/cell/cto\_gd\_ld-eng.php

90 **Government of Canada.** Safety of Human Cells, Tissues and Organs for Transplantation Regulations (SOR/2007-118) [Internet]. Available from: http: //laws-lois.justice.gc.ca/eng/regulations/SOR-2007-118/

91 **Boyarsky BJ**, Hall EC, Singer AL, Montgomery RA, Gebo KA, Segev DL. Estimating the potential pool of HIV-infected deceased organ donors in the United States. *Am J Transplant* 2011; **11**: 1209-1217 [PMID: 21443677 DOI: 10.1111/j.1600-6143.2011.03506.x]

92 **Muller E**, Barday Z, Mendelson M, Kahn D. Renal transplantation between HIV-positive donors and recipients justified. *S Afr Med J* 2012; **102**: 497-498 [PMID: 22668948]

93 **Library of Congress.** S.330 — 113th Congress (2013-2014) HIV Organ Policy Equity Act [Internet]. Available from: http: //beta.congress.gov/bill/113th/senate-bill/330

94 **Ragni MV**, Belle SH, Im K, Neff G, Roland M, Stock P, Heaton N, Humar A, Fung JF. Survival of human immunodeficiency virus-infected liver transplant recipients. *J Infect Dis* 2003; **188**: 1412-1420 [PMID: 14624365 DOI: 10.1086/379254]

95 **Vennarecci G**, Ettorre GM, Antonini M, Santoro R, Perracchio L, Visco G, Santoro E. Liver transplantation in HIV-positive patients. *Transplant Proc* 2007; **39**: 1936-1938 [PMID: 17692658 DOI: 10.1016/j.transproceed.2007.05.076]

96 **Anadol E**, Beckebaum S, Radecke K, Paul A, Zoufaly A, Bickel M, Hitzenbichler F, Ganten T, Kittner J, Stoll M, Berg C, Manekeller S, Kalff JC, Sauerbruch T, Rockstroh JK, Spengler U. Orthotopic liver transplantation in human-immunodeficiency-virus-positive patients in Germany. *AIDS Res Treat* 2012; **2012**: 197501 [PMID: 22900154 DOI: 10.1155/2012/197501]

97 **Tateo M**, Roque-Afonso AM, Antonini TM, Medja F, Lombes A, Jardel C, Teicher E, Sebagh M, Roche B, Castaing D, Samuel D, Duclos-Vallee JC. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. *AIDS* 2009; **23**: 1069-1076 [PMID: 19417577 DOI: 10.1097/QAD.0b013e32832c2a37]

98 **Schreibman I**, Gaynor JJ, Jayaweera D, Pyrsopoulos N, Weppler D, Tzakis A, Schiff ER, Regev A. Outcomes after orthotopic liver transplantation in 15 HIV-infected patients. *Transplantation* 2007; **84**: 697-705 [PMID: 17893602 DOI: 10.1097/01.tp.0000282873.24648.5b]

99 **Norris S**, Taylor C, Muiesan P, Portmann BC, Knisely AS, Bowles M, Rela M, Heaton N, O'Grady JG. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. *Liver Transpl* 2004; **10**: 1271-1278 [PMID: 15376307 DOI: 10.1002/lt.20233]

100 **Silveira FP**, Kusne S, AST Infectious Diseases Community of Practice. Candida infections in solid organ transplantation. *Am J Transplant* 2013; **13** Suppl 4: 220-227 [PMID: 23465015 DOI: 10.1111/ajt.12114]

101 **Razonable RR**, Humar A, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. *Am J Transplant* 2013; **13** Suppl 4: 93-106 [PMID: 23465003 DOI: 10.1111/ajt.12103]

102 **Tseng A**. Antiretroviral Interactions With Transplant Medications [Internet]. Available from: http: //www.hivclinic.ca/main/drugs\_interact\_files/transplant-int.pdf

**P-Reviewers:** Diamantis I, Fisher RA, He JY, Kawaguchi T **S-Editor:** Gou SX

 **L-Editor: E-Editor:**

**Table 1 Summary of outcomes post orthotopic liver transplant in hepatitis C virus/ human immunodeficiency virus co-infection**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Publication1** | **Study period** | **Country** | **Patients** | **Median follow-up****(mo)** | **Survival** | **Graft survival** |
| Terrault *et al*[2] | 2003-2010 | United States | 89 | 32 | 76% 1 yr60% 3 yr | 72% 1 yr53% 3 yr |
| Miro *et al*[41] | 2002-2006 | Spain | 84 | 44 | 88% 1 yr62% 3 yr54% 5 yr | NR |
| Duclos-Vallée *et al*[43] | 1999-2005 | France | 35 | 44 | 82% 1 yr73% 2 yr51% 5 yr | NR |
| De Vera *et al*[44] | 1997-2005 | United States | 27 | 27 | 67% 1 yr56% 3 yr33% 5 yr | 63% 1 yr52% 3 yr31% 5 yr |
| Ragni *et al*[94] | 1997-2001 | United States | 15 | 17 | 80% 1 yr57% 3 yr36% 5 yr | NR |
| Vennarecci *et al*[95] | 2002-2006 | Italy | 11 | 26 | 83% 1 yr58% 3 yr2 | NR |
| Anadol *et al*[96] | 1997-2011 | Germany | 19 | 613 | 58% 5 yr | NR |

1Studies with ≥ 10 patients; 2Survival reported for cohort of 12, including one hepatitis B virus/human immunodeficiency virus co-infected patient; 3For all patients. NR: Not reported.

**Table 2 Summary of outcomes post orthotopic liver transplant in hepatitis B virus/human immunodeficiency virus co-infection**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Publication** | **Study period** | **Country** | **Patients** | **Median follow-up (mo)** | **Survival** | **Graft survival** | **Comments** |
| Coffin *et al*[49] | 2001-2007 | United States | 22 | 42 | 85% 1 yr85% 3 yr | 85% 1 yr85% 3 yr | About 50% had detectable HBV pre transplant |
| Tateo *et al*[97] | 1999-2007 | France | 13 | 32 | 100% | 100% | 1 co-infected with HDV, 2 with HCV, 4 with HCV and HDV |
| Anadol *et al*[96] | 1997-2011 | Germany | 10 | 611 | 90% 1 yr80% 5 yr | NR |  |
| Schreibman *et al*[98] | 1999-2006 | United States | 8 | NR | 75% 1 yr75% 3 yr | NR | 2 co-infected with HCV, 1 fulminant hepatic failure |
| Norris *et al*[99] | 1995-2003 | United Kingdom | 4 | 22 | 100% 1 yr | NR |  |

1For entire series. HBV: Hepatitis B virus; HCV: Hepatitis C virus; NR: Not reported; HDV: Hepatitis D virus.

**Table 3 Contraindications to liver transplantation in human immunodeficiency virus positive patient**

|  |  |
| --- | --- |
| **Condition** | **Comment** |
| Progressive multifocal leukoencephalopathy (PML) |  |
| Cryptosporidiosis | Chronic intestinal > 1 mo duration |
| Lymphoma | Primary CNS |
| Visceral Kaposi’s sarcoma | Cutaneous KS considered if remission with immune reconstitution and no active/vascular residual cutaneous lesions on physical exam and chest CT scan |
| Encephalopathy, HIV-related | Unless diagnosed prior to HAART and resolved on HAART with marked improvement in mental status and increased CD4+ T-cell count and no evidence of progression of CNS disease AND are otherwise considered eligible from a functional standpoint |

HIV: Human immunodeficiency virus; CNS: Central nervous system; CT: Computerized tomography; KS: Kaposi’s sarcoma; HAART: Highly active anti retroviral therapy.

**Table 4 Post transplant prophylaxis**

|  |  |
| --- | --- |
| **Post transplant prophylaxis** | **Comment** |
| PJP prophylaxis | Trimethoprim/sulfamethoxazole SS one tablet daily life longAlternatives: Dapsone 100 mg daily, pentamidine 300 mg inhaled or *iv* monthly or atovaquone 1500 mg daily[54] |
| CMV | Valganciclovir 900 mg daily1; oral (1 g *tid*) or *iv* (5 mg/kg daily) ganciclovir for 3 mo in D+/R-; prophylaxis or pre-emptive monitoring and therapy in R+ |
| Fungal | High risk patients2 should receive Fluconazole 400 mg *po* daily × 14 d minimum[100] |
| HBV (in HBV co-infected patients) | Life long HBIG targeting 100 IU/L PLUS either tenofovir or entecavir |

1Valganciclovir is not FDA approved for use in liver transplantation; many centers use this agent off label[101]; 2High risk features include repeat or prolonged surgery, high transfusion requirements, renal failure, colonization with Candida or Choledochojejunostomy[100]. PJP: *Pneumocystis jeroveci* pneumonia; SS: Single strength; CMV: Cytomegalovirus; HBV: Hepatitis B virus; HBIG: Hepatitis B immunoglobulin; FDA: United States Food and Drug Administration.

**Table 5 Drug-drug interactions: Antiretrovirals and immunosuppressants[54,102]**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Steroids** | **Calcineurin inhibitors****(cyclosporine/tacrolimus)** | **mTOR inhibitors****(sirolimus, everolimus)** | **Antimetabolites****(mycofenylate mofitl)** |
| PI | Significant increase | Significant increase in immunosuppression levels in general.Calcineurin inhibitor levels may increase or decrease with exposure to either amprenavir or fosamprenavir | Significant increase in immunosuppression levels | Generally no effect; levels may decrease with nelfinavir, lopinavir/ritonavir |
| NNRTI | Mild decrease in level | Mild decrease in level | Mild decrease in level | No effect on immunosuppressant levels. May decrease nevirapine levels |
| NRTI | No effect | No effect | No effect | May be increased with zidovudine |
| Integrase inhibitors | No effect | Increased with elvitegravir | Increased with elvitegravir | Increased with elvitegravir |
| CCR5-agonists | No effect |
| Fusion inhibitors | No effect |

PI: Protease inhibitor; mTOR: Mammalian target of rapamycin; NNRTI: Non-nucleoside reverse transcriptase inhibitors; NRTI: Nucleoside reverse transcriptase inhibitors; CCR5: Chemokine receptor type.